Pavel Klener
-
PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population
J. Karolova, M. Radek, K. Helman, M. Spacek, Marek Trněný, Pavel Klener
2020, Vol. 66, Issue 4, pp. 117-122 -
Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma
P. Vockova, M. Svaton, J. Karolova, E. Pokorna, Martin Vokurka, Pavel Klener
2020, Vol. 66, Issue 1, pp. 17-23 -
Molecularly-Targeted and Biological Anti-Cancer Therapy
P. Klener, Jr., Pavel Klener
2012, Vol. 58, Issue 1, pp. 1-6
The following names might also represent this author:
P. Klener
-
In Vivo Growth of Mantle Cell Lymphoma Xenografts in Immunodeficient Mice Is Positively Regulated by VEGF and Associated with Significant Up-regulation of CD31/PECAM1
Jan Molinský, M. Klánová, B. Maswabi, T. Soukup, M. Trněný, E. Nečas, J. Živný, P. Klener
2013, Vol. 59, Issue 1, pp. 26-31
P. Klener, Jr.
-
Comparison of Plasma Osteopontin Levels between Patients with Borderline Ovarian Tumours and Serous Ovarian Carcinoma
Jan H. Živný, S. Leahomschi, P. Klener, Jr., J. Živný, M. Haluzík, D. Cibula
2016, Vol. 62, Issue 6, pp. 258-262 -
Molecularly-Targeted and Biological Anti-Cancer Therapy
P. Klener, Jr., Pavel Klener
2012, Vol. 58, Issue 1, pp. 1-6
